AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%
Last update at 2025-04-17T20:10:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2023-12-31 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
| Income before tax | -195.41900M | -154.66100M | -154.66100M | -251.50500M | -251.50500M |
| Minority interest | - | - | - | - | - |
| Net income | -240.05300M | -155.80000M | -155.80000M | -230.02600M | -230.02600M |
| Selling general administrative | 48.42M | 141.06M | 141.06M | 71.46M | 71.46M |
| Selling and marketing expenses | 57.46M | 69.05M | 69.05M | 64.78M | 64.78M |
| Gross profit | 67.03M | 205.33M | 205.33M | 32.52M | 32.52M |
| Reconciled depreciation | 2.83M | 2.33M | 2.33M | 2.63M | 2.63M |
| Ebit | -150.02900M | -110.44300M | -123.62700M | -226.34500M | -261.72000M |
| Ebitda | -146.76200M | -108.05500M | -98.83500M | -223.71500M | -233.16500M |
| Depreciation and amortization | 3.27M | 2.39M | 24.79M | 2.63M | 28.55M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -165.98600M | -123.62700M | -123.62700M | -261.72000M | -261.72000M |
| Other operating expenses | 235.54M | 333.54M | 333.54M | 295.64M | 295.64M |
| Interest expense | 46.33M | 36.92M | 36.92M | 18.34M | 18.34M |
| Tax provision | -2.99100M | 1.14M | 1.14M | -21.47900M | -21.47900M |
| Interest income | 6.62M | 17.97M | 17.97M | 0.07M | 0.07M |
| Net interest income | -39.57700M | -18.95400M | -18.95400M | -18.27400M | -18.27400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 39.11M | 1.14M | 1.14M | -21.47900M | -21.47900M |
| Total revenue | 69.56M | 209.91M | 209.91M | 33.92M | 33.92M |
| Total operating expenses | 233.01M | 328.96M | 328.96M | 294.24M | 294.24M |
| Cost of revenue | 2.53M | 4.58M | 4.58M | 1.39M | 1.39M |
| Total other income expense net | -29.43300M | -33.55700M | -31.03400M | 10.21M | 10.21M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -178.50700M | -155.80000M | -155.80000M | -230.02600M | -230.02600M |
| Net income applicable to common shares | - | -155.80000M | -155.80000M | -230.02600M | -230.02600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
| Total assets | 354.78M | 529.17M | 529.17M | 617.97M | 617.97M |
| Intangible assets | - | 14.36M | 14.36M | 13.58M | 13.58M |
| Earning assets | - | - | - | - | - |
| Other current assets | 16.33M | 23.50M | 28.04M | 17.30M | 17.30M |
| Total liab | 503.03M | 440.44M | 440.44M | 451.88M | 451.88M |
| Total stockholder equity | -148.24900M | 88.73M | 88.73M | 166.09M | 166.09M |
| Deferred long term liab | - | 0.95M | 0.95M | 0.63M | 0.63M |
| Other current liab | 49.17M | 68.49M | 73.03M | 49.47M | 50.50M |
| Common stock | 7.31M | 7.31M | 7.31M | 6.45M | 6.45M |
| Capital stock | 7.31M | 7.31M | 7.31M | 6.45M | 6.45M |
| Retained earnings | -1335.47200M | -1080.68500M | -1080.68500M | -924.88500M | -924.88500M |
| Other liab | - | 25.33M | 25.33M | 65.14M | 65.14M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 28.61M | 28.61M | 27.37M | 27.37M |
| Cash | 278.60M | 326.44M | 326.44M | 466.54M | 466.54M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 67.67M | 98.96M | 98.96M | 73.94M | 73.94M |
| Current deferred revenue | - | - | - | 3.75M | 3.75M |
| Net debt | -154.22100M | -209.06600M | -209.06600M | -364.79300M | -364.79300M |
| Short term debt | 2.93M | 1.10M | 13.57M | 8.63M | 7.60M |
| Short long term debt | - | 12.47M | 12.47M | 6.58M | 6.58M |
| Short long term debt total | 124.38M | 117.38M | 117.38M | 101.75M | 101.75M |
| Other stockholder equity | 1180.00M | 1165.73M | 1006.77M | 981.70M | 981.70M |
| Property plant equipment | - | 9.98M | 9.98M | 11.23M | 11.23M |
| Total current assets | 336.29M | 446.01M | 446.01M | 525.18M | 525.18M |
| Long term investments | 1.65M | 31.15M | 31.15M | 41.24M | 41.24M |
| Net tangible assets | - | 75.32M | 75.32M | 153.14M | 153.14M |
| Short term investments | - | - | - | - | - |
| Net receivables | 25.18M | 72.97M | 77.71M | 30.22M | 30.22M |
| Long term debt | 112.73M | 97.24M | 97.24M | 125.10M | 125.10M |
| Inventory | 16.18M | 18.56M | 18.56M | 11.12M | 11.12M |
| Accounts payable | 15.57M | 12.35M | 12.35M | 12.08M | 12.08M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.09300M | 155.33M | 155.33M | 102.83M | 102.83M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.71M | 0.90M | 0.90M | 0.69M | 0.69M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 18.49M | 83.15M | 83.15M | 92.79M | 92.79M |
| Capital lease obligations | 11.65M | 7.66M | 7.66M | 8.02M | 8.02M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
| Investments | -2.39900M | -2.50800M | -2.50800M | -6.67300M | -6.67300M |
| Change to liabilities | - | 0.31M | 0.31M | 6.80M | 6.80M |
| Total cashflows from investing activities | - | -2.50800M | -2.50800M | -6.67300M | -6.67300M |
| Net borrowings | - | -6.50200M | -6.50200M | 48.61M | 48.61M |
| Total cash from financing activities | 73.88M | -0.59300M | -0.59300M | 267.39M | 267.39M |
| Change to operating activities | - | 16.55M | 16.55M | 6.16M | 6.16M |
| Net income | -240.05300M | -155.80000M | -155.80000M | -230.02600M | -230.02600M |
| Change in cash | -47.84300M | -140.10300M | -140.10300M | 27.35M | 27.35M |
| Begin period cash flow | 326.44M | 466.54M | 466.54M | 439.19M | 439.19M |
| End period cash flow | 278.60M | 326.44M | 326.44M | 466.54M | 466.54M |
| Total cash from operating activities | -118.68600M | -136.79400M | -136.79400M | -233.37800M | -233.37800M |
| Issuance of capital stock | -0.06200M | 6.13M | 6.13M | 188.94M | 0.00000M |
| Depreciation | 3.27M | 2.33M | 2.33M | 2.63M | 2.63M |
| Other cashflows from investing activities | - | -0.21000M | -0.21000M | -0.29700M | -0.29700M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 1.61M | -8.96400M | -8.96400M | -3.02200M | -3.02200M |
| Change to account receivables | 47.79M | -42.75300M | -42.75300M | -30.21800M | -30.21800M |
| Sale purchase of stock | - | -0.22100M | -0.22100M | 0.00000M | 0.00000M |
| Other cashflows from financing activities | 73.88M | -4.32000M | -5.49100M | 218.78M | 267.59M |
| Change to netincome | - | 49.69M | 49.69M | 14.30M | 14.30M |
| Capital expenditures | 3.22M | 2.30M | 2.30M | 6.38M | 6.38M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 44.27M | -33.01000M | -33.01000M | -20.28000M | -20.28000M |
| Stock based compensation | 13.49M | 49.32M | 49.32M | 60.48M | 60.48M |
| Other non cash items | 23.23M | 1.07M | 1.07M | -24.70300M | -24.70300M |
| Free cash flow | -121.90200M | -139.09200M | -139.09200M | -239.75400M | -239.75400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics SA |
0.05 4.31% | 1.21 | - | - | 4.39 | 2.58 | 2.16 | -1.4269 |
| NVO Novo Nordisk A/S |
-4.8 7.63% | 58.08 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.79 4.46% | 59.70 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.21 0.66% | 489.10 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
13.88 2.53% | 563.16 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
BiopOle, Epalinges, Switzerland, 1066
| Name | Title | Year Born |
|---|---|---|
| Dr. Ameet Mallik M.B.A., M.S. | CEO & Director | 1972 |
| Dr. Christopher J. Martin DPHIL, Ph.D. | Co-Founder & Non-Exec. Director | 1959 |
| Ms. Jennifer Creel | Chief Financial Officer | 1971 |
| Dr. Michael Mulkerrin Ph.D. | Chief Technical Operations Officer | NA |
| Dr. Patrick van Berkel Ph.D. | Chief Scientific Officer | 1968 |
| Amanda Hamilton | Investor Relations Officer | NA |
| Ms. Susan Romanus | Chief Compliance & Quality Officer | 1965 |
| Mr. Peter J. Graham Esq. | Chief Legal Officer | 1967 |
| Ms. Kimberly Pope | Sr. VP & Chief People Officer | 1966 |
| Dr. Joseph Camardo Ph.D. | Chief Medical Officer | 1953 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...